Cargando…

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of the improvements in the life quality of patients, their effectiveness is compromised by several disadvantages. This represents a demand for developing new effective strategies with focusing on tumor cells an...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hojjat-Farsangi, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159824/ https://www.ncbi.nlm.nih.gov/pubmed/25110867 http://dx.doi.org/10.3390/ijms150813768

Ejemplares similares

New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
por: Lin, Nancy U, et al.
Publicado: (2004)

A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells
por: Ghaderi, Amineh, et al.
Publicado: (2023)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
por: Hojjat-Farsangi, M., et al.
Publicado: (2018)

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
por: Daneshmanesh, Amir Hossein, et al.
Publicado: (2018)

Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2015)

Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?
por: Rendell, Aimee, et al.
Publicado: (2022)

Receptor Tyrosine Kinase-Targeted Cancer Therapy
por: Yamaoka, Toshimitsu, et al.
Publicado: (2018)

Comparative Expression Profile of Orphan Receptor Tyrosine Kinase ROR1 in Iranian Patients with Lymphoid and Myeloid Leukemias
por: Shabani, Mahdi, et al.
Publicado: (2011)

Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes
por: Little, Peter J., et al.
Publicado: (2009)

Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase
por: Mattila, Elina, et al.
Publicado: (2010)

Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
por: Lauter, Markus, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
por: Park, Hyunjung, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B-Cell Signaling
por: Ratzon, Einav, et al.
Publicado: (2017)

The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib(®))
por: GAUMANN, ANDREAS K.A., et al.
Publicado: (2014)

Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target
por: Pidkovka, Nataliya, et al.
Publicado: (2023)

A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
por: Ghaderi, Amineh, et al.
Publicado: (2022)

Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer
por: Elferink, Lisa A., et al.
Publicado: (2011)

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
por: Zhou, Jianbiao, et al.
Publicado: (2009)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1(+) CLL cells
por: Ghaderi, Amineh, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
por: García-Merino, Antonio
Publicado: (2021)

Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome
por: Secombe, Kate R., et al.
Publicado: (2020)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
por: Abbaspour Babaei, Maryam, et al.
Publicado: (2016)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Recent developments in receptor tyrosine kinases targeted anticancer therapy
por: Raval, Samir H., et al.
Publicado: (2016)

New, potent, small molecule agonists of tyrosine kinase receptors attenuate dry eye disease
por: Yu, Zhiyuan, et al.
Publicado: (2022)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
por: Masbuchin, Ainun Nizar, et al.
Publicado: (2022)

Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19
por: Rezaei, Mitra, et al.
Publicado: (2020)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
por: Xu, Wenjing, et al.
Publicado: (2022)

AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
por: Goyette, Marie-Anne, et al.
Publicado: (2022)

Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies
por: Wei, Ying, et al.
Publicado: (2023)

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
por: Onken, Julia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_teicn1ndvd9j7im77bj73kdrqu